Organ-on-chip startup Anivance AI closes NT$200 million Series A with all existing investors following on

Anivance AI, founded in 2024 to speed drug testing with AI and organ-on-chip models, has raised a NT$200 million (about US$6 million) Series A in which every existing investor took part. Funds go to lab infrastructure and overseas expansion; its inhalation lung-chip was picked for a US FNIH pilot, and it has over 30 clients and a US subsidiary.